• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国国家医疗服务体系(NHS)与制药行业:存在有害相互作用的高风险。

The NHS and the pharmaceutical industry: High risk of harmful interactions.

作者信息

McCartney Margaret

机构信息

University of St Andrews, St Andrews, Fife, Scotland.

出版信息

Future Healthc J. 2025 Jun 30;12(2):100257. doi: 10.1016/j.fhj.2025.100257. eCollection 2025 Jun.

DOI:10.1016/j.fhj.2025.100257
PMID:40692637
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12277477/
Abstract

The pharmaceutical industry has been responsible for many interventions of great benefit to patients. However, great harm to patients and healthcare systems have been created through conflicts of interest, when the behaviours of individual doctors and healthcare systems have been compromised and patient harm has resulted. The interests of the pharmaceutical industry and the NHS cannot be assumed to overlap. This means that medical decision making should be as independent and unbiased as possible. Transparency about conflicts is important, but should be a means to the end it must be part of a system which stops conflicts harming patients and healthcare systems. Given the uncertainty of how the benefits of transparency can be used in practice, it is an imperative that conflicts are avoided, and not just 'managed'.

摘要

制药行业促成了许多对患者大有裨益的干预措施。然而,当个别医生的行为和医疗保健系统受到利益冲突的影响并导致患者受到伤害时,就会对患者和医疗保健系统造成巨大损害。不能假定制药行业和英国国家医疗服务体系(NHS)的利益是重叠的。这意味着医疗决策应尽可能独立且公正。冲突的透明度很重要,但它应该是实现目的的一种手段,它必须成为一个防止冲突损害患者和医疗保健系统的体系的一部分。鉴于在实践中如何利用透明度带来的益处存在不确定性,必须避免冲突,而不仅仅是“管理”冲突。

相似文献

1
The NHS and the pharmaceutical industry: High risk of harmful interactions.英国国家医疗服务体系(NHS)与制药行业:存在有害相互作用的高风险。
Future Healthc J. 2025 Jun 30;12(2):100257. doi: 10.1016/j.fhj.2025.100257. eCollection 2025 Jun.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Sexual Harassment and Prevention Training性骚扰与预防培训
4
Short-Term Memory Impairment短期记忆障碍
5
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.成年自闭症患者的就业生活经历:系统检索与综述
Autism Adulthood. 2024 Dec 2;6(4):495-509. doi: 10.1089/aut.2022.0114. eCollection 2024 Dec.
6
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
7
Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research.妊娠期和产褥期的血栓预防:一项系统评价和经济评估,以估算未来研究的价值。
Health Technol Assess. 2024 Mar;28(9):1-176. doi: 10.3310/DFWT3873.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
10
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.

本文引用的文献

1
The Political Sociology of NICE: Investigating Pharmaceutical Cost-Effectiveness Regulation in the UK.英国国家卫生与临床优化研究所的政治社会学:探究英国的药品成本效益监管
Sociol Health Illn. 2025 Jan;47(1):e13878. doi: 10.1111/1467-9566.13878.
2
'You feel like you've been duped': is the current system for health professionals declaring potential conflicts of interest in the UK fit for purpose? A mixed methods study.“你觉得自己好像被骗了”:英国现行的健康专业人员申报潜在利益冲突的制度是否合理?一项混合方法研究。
BMJ Open. 2023 Jul 26;13(7):e072996. doi: 10.1136/bmjopen-2023-072996.
3
"You have to be above reproach": why doctors need to get better at managing their conflicts of interest.“你必须无可指责”:为何医生需要更善于处理利益冲突
BMJ. 2023 Jul 26;382:1646. doi: 10.1136/bmj.p1646.
4
Medical royal colleges receive millions from drug and medical devices companies.医学皇家学院从制药和医疗器械公司获得数百万资金。
BMJ. 2023 Jul 26;382:1658. doi: 10.1136/bmj.p1658.
5
Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.英国患者组织的行业资助:商业决定因素、资金集中和疾病流行情况的回顾性研究。
BMJ Open. 2023 Jun 27;13(6):e071138. doi: 10.1136/bmjopen-2022-071138.
6
Policies on doctors' declaration of interests in medical organisations: a thematic analysis.医生在医疗机构申报利益政策:主题分析。
J R Soc Med. 2023 Sep;116(9):295-306. doi: 10.1177/01410768231181248. Epub 2023 Jun 8.
7
Novo Nordisk suspended from industry body over serious breaches.诺和诺德因严重违规行为被行业机构暂停资格。
BMJ. 2023 Mar 17;380:634. doi: 10.1136/bmj.p634.
8
How are declarations of interest working? A cross-sectional study in declarations of interest in healthcare practice in Scotland and England in 2020/2021.利益声明如何运作?2020/2021 年苏格兰和英格兰医疗实践中利益声明的横断面研究。
BMJ Open. 2022 Nov 4;12(11):e065365. doi: 10.1136/bmjopen-2022-065365.
9
Investigation into financial conflicts of interest and screening for atrial fibrillation in the UK: a cross-sectional study.英国利益冲突的财务调查及心房颤动筛查:一项横断面研究。
BMJ Evid Based Med. 2023 Feb;28(1):15-20. doi: 10.1136/bmjebm-2022-112004. Epub 2022 Oct 10.
10
Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.应对北美及其他地区的阿片类药物危机:斯坦福-柳叶刀委员会的建议
Lancet. 2022 Feb 5;399(10324):555-604. doi: 10.1016/S0140-6736(21)02252-2. Epub 2022 Feb 2.